Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14 | Direct | 21,872 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 21,872 · Balance 21,872 F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 21,872 | $0.00 Strike: $30.76 | $0.00 |
DisclosureSEC source: 0001821210-26-000002 · form4-05182026_080557.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,872 Underlying: Common Stock · 21,872 shares Expires 2036-05-14 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 14, 2027 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| August 28, 2025 Filed Sep 2, 2025 21:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | OtherCommon Stock | 6,618,033 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-083535 · ownership.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. F1 · price: In-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 14,522 | $0.00 Strike: $34.23 | $0.00 |
DisclosureSEC source: 0001415889-25-013411 · form4-05162025_080555.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,522 Underlying: Common Stock · 14,522 shares Expires 2035-05-15 F1 · derivative.exercise_date: 1. The stock option shall vest in full on the earlier to occur of (i) May 15, 2026 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| November 05, 2024 Filed Nov 5, 2024 22:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 600,000 | $30.30 | $18,181,500.00 |
DisclosureSEC source: 0001213900-24-094654 · ownership.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,618,033 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 22:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,000,000 | $30.30 | $121,210,000.00 |
DisclosureSEC source: 0001213900-24-094654 · ownership.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,218,033 Read SEC document |
| May 29, 2024 Filed May 31, 2024 12:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 6,336 | $0.00 Strike: $29.33 | $0.00 |
DisclosureSEC source: 0001415889-24-014968 · form4-05312024_120537.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,336 Underlying: Common Stock · 6,336 shares Expires 2034-05-29 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 5,224 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001415889-23-008847 · form4-05262023_040501.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,224 Underlying: Common Stock · 5,224 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 25, 2024 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 4,742 | $0.00 Strike: $41.33 | $0.00 |
DisclosureSEC source: 0001104659-22-064249 · tm2216688-4_4seq1.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,742 Underlying: Common Stock · 4,742 shares Expires 2032-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2023 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 20, 2021 Filed Jun 14, 2021 20:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 7,246 | $0.00 Strike: $32.50 | $0.00 |
DisclosureSEC source: 0000899243-21-023563 · doc4.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,246 Underlying: Common Stock · 7,246 shares Expires 2031-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2022 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:41 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries C Preferred Stock · Derivative | 1,810,126 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023393 · doc4.xml · derivative · entry 4 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F4 · shares: Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F4 · derivative.underlying_shares: Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:41 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 77,950,712 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023393 · doc4.xml · derivative · entry 3 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,080,352 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F3 · shares: Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F3 · derivative.underlying_shares: Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:41 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 240,668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023393 · doc4.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,166,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:41 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 12,080,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023393 · doc4.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,925,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries C Preferred Stock · Derivative | 1,786,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024369 · doc4a.xml · derivative · entry 4 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233,052.23 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F4 · derivative.underlying_shares: Includes 15,525.15 shares of common stock received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 75,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024369 · doc4a.xml · derivative · entry 3 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,139,645.04 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F3 · derivative.underlying_shares: Includes 1,010,004.14 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 233,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024369 · doc4a.xml · nonDerivative · entry 2 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,218,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 10,139,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024369 · doc4a.xml · nonDerivative · entry 1 Valor IV Pharma Holdings, LLC · CIK 0001821186 · 10% owner Valor Management L.P. · CIK 0001822428 · 10% owner Valor Equity Capital IV LLC · CIK 0001821936 · 10% owner Valor Equity Associates IV L.P. · CIK 0001822427 · 10% owner VALOR EQUITY PARTNERS IV L.P. · CIK 0001705506 · 10% owner VALOR EQUITY PARTNERS IV-A L.P. · CIK 0001705542 · 10% owner VALOR EQUITY PARTNERS IV-B L.P. · CIK 0001705512 · 10% owner Gracias Antonio J. · CIK 0001495158 · Director · 10% owner Sabater Juan A. · CIK 0001821210 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,984,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · ownership.direct: Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein. Read SEC document |
| August 18, 2020 Filed Aug 21, 2020 00:02 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 9,012 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023125 · doc4.xml · derivative · entry 1 Sabater Juan A. · CIK 0001821210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,012 Underlying: Common Stock · 9,012 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in three equal annual installments beginning on August 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.